IKZF1 plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL / MRD2008 trial
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13972 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Yoshikiyo Ito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Imamura General Hospital, Kagoshima, Japan. Hauptthemen laut MEDLINE: Ikaros Transcription Factor, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objective
The prognostic significance of IKZF1 plus in adult Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL) patients had remained to be clarified.
Methods
We conducted a prospective, multicenter study, the ALL/MRD2008 trial, and investigated the clinical significance of IKZF1 plus .
Results
From December 2008 to November 2013, 38 untreated Ph+ ALL patients were enrolled. At the end of the induction, 97.4% of patients (37/38) achieved complete hematological remission, with MRD‐negativity of 48.6% (18/37). There were 19 patients with IKZF1 plus , 13 with IKZF1 deletion alone ( ΔIKZF1 ) and 4 with no IKZF1 deletions (no ΔIKZF1 ). The probability of 3‐year DFS and OS in these Ph+ ALL patients were 50% (95% confidence interval [CI], 33–65) and 55% (95% CI, 38–69), respectively. There was no significant difference between IKZF1 plus , ΔIKZF1 , and no ΔIKZF1 in DFS (47%, 54%, 75% [ p = .63]) or OS (47%, 62%, NA [ p = .39]).
Conclusions
We revealed no relationship between IKZF1 plus status and survival outcomes in Ph+ ALL patients treated with imatinib/dasatinib combination chemotherapy. Further investigations are warranted to clarify the prognostic significance of IKZF1 plus in adult Ph+ ALL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
- Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
- Division of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
- Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
Zitieren
APA
Ito, Y., Ozawa, H., Eto, T., Miyamoto, T., Kamimura, T., Ogawa, R., Uchida, N., Wake, A., Fujisaki, T., Ohno, Y., Takase, K., Okumura, H., Takamatsu, Y., Kawano, N., Akashi, K., & Nagafuji, K. (2023). IKZF1 plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL / MRD2008 trial. European Journal of Haematology. https://doi.org/10.1111/ejh.13972
Vancouver
Ito Y, Ozawa H, Eto T, Miyamoto T, Kamimura T, Ogawa R, et al. IKZF1 plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL / MRD2008 trial. European Journal of Haematology. 2023. doi:10.1111/ejh.13972
BibTeX
@article{Ito2023,
author = {Ito, Yoshikiyo and Ozawa, Hidetoshi and Eto, Tetsuya and Miyamoto, Toshihiro and Kamimura, Tomohiko and Ogawa, Ryosuke and Uchida, Naoyuki and Wake, Atsusi and Fujisaki, Tomoaki and Ohno, Yuju and Takase, Ken and Okumura, Hirokazu and Takamatsu, Yasushi and Kawano, Noriaki and Akashi, Koichi and Nagafuji, Koji},
title = {IKZF1 plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL / MRD2008 trial},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13972}
}
EUVIMED